IRD on Nasdaq

Opus Genetics, Inc.

American pharmaceutical preparations company based in Farmington Hills.

Price unavailable

Last updated Oct 18, 2026.

Overview

Compare with Arbutus Biopharma, Pyxis Oncology, Inc. or CV Sciences, Inc., or pick any stock.

  • TickerIRD on Nasdaq
  • IndustryPharmaceutical Preparations
  • HeadquartersDE
  • Incorporated inDE2
  • Business address8 Davis Drive, Suite 220, Durham, Nc 277132
  • Filer categoryNon-accelerated filer, Smaller reporting company2

See how the biggest companies compare on our leaderboards

Financials

From the company’s reports to the SEC. Every number links to the filing it came from.

Key numbers, fiscal 2025

-271.9%Operating margin3
-349.3%Net margin3
29.1%Revenue growth, 20253
-323.1%Return on equity3
0.07×Debt to equity3

Where the money goes

Where each dollar of revenue went, fiscal 2025

  • Other costs100¢$14.2M

Out of $14.2M in revenue.3 The company lost money this year.

Financial statements

Revenue456783$14.2M in 2025+373% since 2019
0$10.0M$20.0M$30.0M$40.0M2019: $3.0M$3.0M20192020: $0$020202021: $589.0K$589.0K20212022: $39.9M$39.9M2022+6666%2023: $19.0M$19.0M2023−52%2024: $11.0M$11.0M2024−42%2025: $14.2M$14.2M2025+29%
Operating income956783-$38.6M in 2025+821% since 2019
-$75.0M-$50.0M-$25.0M0$25.0M2019: -$4.2M-$4.2M20192020: -$20.0M-$20.0M2020+376%2021: -$22.7M-$22.7M2021+14%2022: $18.2M$18.2M20222023: -$10.6M-$10.6M20232024: -$62.1M-$62.1M2024+488%2025: -$38.6M-$38.6M2025−38%
Net income956783-$49.6M in 2025+704% since 2019
-$60.0M-$40.0M-$20.0M0$20.0M2019: -$6.2M-$6.2M20192020: -$24.6M-$24.6M2020+299%2021: -$56.7M-$56.7M2021+130%2022: $17.9M$17.9M20222023: -$10.0M-$10.0M20232024: -$57.5M-$57.5M2024+476%2025: -$49.6M-$49.6M2025−14%

Every line of the income statement as filed: the last 2 fiscal years, latest first.3

Period ending2025-12-312024-12-31
License and collaborations revenue$14.2M$11.0M
Research and development$30.8M$26.9M
General and administrative$22.0M$18.2M
Acquired in-process research and development$0$28.0M
Total operating expenses$52.8M$73.1M
Loss from operations-$38.6M-$62.1M
Fair value change in warrant and other derivative liabilities-$11.5M$72.0K
Financing costs (Note 7)-$1.3M$0
Interest expense-$129.0K$0
Other income, net$2.0M$4.5M
Loss before income taxes-$49.6M-$57.5M
Provision for income taxes$0$0
Net loss-$49.6M-$57.5M
Other comprehensive loss, net of tax$0$0
Comprehensive loss-$49.6M-$57.5M
Basic (in dollars per share)-$0.80-$2.15
Diluted (in dollars per share)-$0.80-$2.15
Basic (in shares)62.2M shares26.7M shares
Diluted (in shares)62.2M shares26.7M shares

Compare Opus Genetics, Inc. with another company

Leadership

Who has led Opus Genetics, Inc., and when. Pick a name to see everywhere that person has worked.

Chief executive

  1. Chang Ho Ahn2008–2012
  2. Peter David Suzdak2013–2018
  3. Douglas J. Swirsky2018–2019
  4. Mina Sooch2020–2023
  5. Richard J. Rodgers2023
  6. George Magrath2023–now

Chair

  1. Chang Ho Ahn2008–2012

President

  1. Rakesh Soni2013–2014
  2. Douglas J. Swirsky2018–2019
  3. Mina Sooch2020–2023
  4. Richard J. Rodgers2023
  5. Benjamin R. Yerxa2024–now

Chief financial officer

  1. Tae Heum Jeong2006–2017
  2. Douglas J. Swirsky2018
  3. Nirav S. Jhaveri2024–2025
  4. Robert E. Gagnon2025–now

Chief operating officer

  1. Rakesh Soni2013–2014
  2. Joseph K. Schachle2023–now
2010201520202025
Board members and other officers (37)

Former names

  • Ocuphire Pharma, Inc.Nov 9, 2020 to Oct 22, 20242
  • REXAHN PHARMACEUTICALS, INC.May 16, 2005 to Nov 9, 20202
  • CORPORATE ROAD SHOW DOT COM INCApr 30, 2003 to Apr 29, 20052
  • FERRARO FRANKApr 29, 2003 to Apr 29, 20032

Timeline

  1. Nov 3, 2023New chief executive George Magrath becomes CEO13
  2. Apr 21, 2023New chief executive Richard J. Rodgers becomes CEO12
  3. Nov 9, 2020New chief executive Mina Sooch becomes CEO14
  4. Nov 16, 2018New chief executive Douglas J. Swirsky becomes CEO15
  5. Feb 6, 2013New chief executive Peter David Suzdak becomes CEO16
  6. Apr 15, 2008New chief executive Chang Ho Ahn becomes CEO17

Filings

382 filings to the SEC since October 2021: 5 annual reports, 15 quarterly reports, 81 major events, 165 insider forms, 25 large holders, 1 private raises, 90 other. The latest 20:

  1. Oct 15, 20268-K EDGAR
  2. Oct 2, 20264 PRIMARY DOCUMENT EDGAR
  3. Sep 11, 20264 EDGAR
  4. Sep 11, 20268-K EDGAR
  5. Sep 9, 20268-K EDGAR
  6. Sep 8, 20264 EDGAR
  7. Sep 8, 20264 EDGAR
  8. Sep 3, 2026144 EDGAR
  9. Aug 14, 2026EFFECT EDGAR
  10. Aug 14, 2026SCHEDULE 13G/A EDGAR
  11. Aug 14, 2026SCHEDULE 13G/A EDGAR
  12. Aug 14, 2026SCHEDULE 13G/A EDGAR
  13. Aug 13, 2026CORRESP EDGAR
  14. Aug 12, 2026UPLOAD EDGAR
  15. Aug 7, 2026S-3 EDGAR
  16. Aug 6, 202610-Q EDGAR
  17. Aug 6, 20268-K EDGAR
  18. Jul 27, 20264 EDGAR
  19. Jul 27, 20264 EDGAR
  20. Jul 27, 20264 EDGAR

The 382 filings since October 2021 can be filtered by form type and year here when JavaScript is on.

Every filing from the last three years, summarized. The full record is on SEC EDGAR.

Insider trades and holders

Large holders

Investors who own more than 5% must tell the SEC: a 13D if they may seek to influence the company, a 13G if they hold passively. 25 such filings since October 2021, the latest 10:

  1. Aug 14, 2026SCHEDULE 13G/A
  2. Aug 14, 2026SCHEDULE 13G/A
  3. Aug 14, 2026SCHEDULE 13G/A
  4. May 20, 2026SCHEDULE 13D/A
  5. May 15, 2026SCHEDULE 13G
  6. May 15, 2026SCHEDULE 13G/A
  7. May 15, 2026SCHEDULE 13G/A
  8. May 15, 2026SCHEDULE 13G/A
  9. May 13, 2026SCHEDULE 13G/A
  10. May 13, 2026SCHEDULE 13G

From Forms 4 and Schedules 13D and 13G filed with the SEC.

Money raised

Private offerings the company reported to the SEC on Form D.

  1. Oct 22, 2024Raised $25.8 million in a private offering of equity Form D: 11 investors so far Form D

Held by these funds

The largest holders among investment managers' 13F reports for the quarter ending Jun 30, 2026, the top 25 of 100. Change is in shares since the quarter before.

FundSharesValueShare of the fundChange
Nantahala Capital Management, LLC6,122,718$25.2M0.8%+4,441,388
Caligan Partners LP6,077,084$25.0M1.2%+2,056
Adage Capital Partners Gp, L.l.c.6,029,775$24.8M0.0%No change
BIOS Capital Management, LP3,683,429$15.1M36.3%No change
BlackRock, Inc.3,116,487$12.8M0.0%+2,968,747
Balyasny Asset Management L.P.3,087,866$12.7M0.0%+369,837
Vanguard Capital Management LLC2,958,683$12.2M0.0%+508,696
Boxer Capital Management, LLC2,815,000$11.6M0.9%+565,000
Trails Edge Capital Partners, LP2,743,658$11.3M1.8%+2,243,658
Millennium Management LLC2,302,101$9.5M0.0%−328,331
Great Point Partners LLC1,970,187$8.1M1.9%+1,645,847
Marshall Wace, Llp1,945,609$8.0M0.0%−367,771
ADAR1 Capital Management, LLC1,783,781$7.3M0.3%−65,223
Goldman Sachs Group Inc1,527,229$6.3M0.0%+1,200,420
Woodline Partners LP1,434,713$5.9M0.0%+80,683
Geode Capital Management, LLC1,367,712$5.6M0.0%+829,365
Boothbay Fund Management, LLC1,189,515$4.9M0.1%+402
Opaleye Management Inc.1,125,000$4.6M0.4%+5,000
SummitTX Capital, L.P.1,007,351$4.1M0.1%New
State Street Corp790,136$3.2M0.0%+590,183
Bleichroeder LP736,842$3.0M0.5%No change
UBS Group AG683,895$2.8M0.0%+426,246
Citadel Advisors LLC665,662$2.7M0.0%+544,762
Morgan Stanley464,900$1.9M0.0%+425,378
Northern Trust Corp442,154$1.8M0.0%+347,739

13F reports cover disclosed long positions in U.S. stocks only.

Sources

The numbers on this page point here. Each one links to the record it came from.

  1. 1
  2. 2
  3. 3
  4. 4
  5. 5
  6. 6
  7. 7
  8. 8
  9. 9
  10. 10
  11. 11
  12. 12
  13. 13
  14. 14
  15. 15
  16. 16
  17. 17
  18. 18
  19. 19
  20. 20
  21. 21
  22. 22
  23. 23
  24. 24
  25. 25
  26. 26
  27. 27
  28. 28
  29. 29
  30. 30
  31. 31
  32. 32
  33. 33
  34. 34
  35. 35
  36. 36
  37. 37
  38. 38
  39. 39
  40. 40
  41. 41
  42. 42
  43. 43
  44. 44
  45. 45
  46. 46
  47. 47
  48. 48
  49. 49
  50. 50
  51. 51
  52. 52
  53. 53
  54. 54
  55. 55
  56. 56
  57. 57
  58. 58